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Abstract 
The galactoside-binding protein galectin-3 is 
increasingly recognized as an important player 
in cancer development, progression, and 
metastasis via its interactions with various 
galactoside-terminated glycans. We have 
previously shown that circulating galectin-3, 
that is increased by up to 30-fold in cancer 
patients, promotes blood-borne metastasis in an 
animal cancer model. This effect is partly 
attributable to galectin-3’s interaction with 
unknown receptor(s) on vascular endothelial 
cells and causes endothelial secretion of several 
metastasis-promoting cytokines. Here, we 
sought to identify the galectin-3-binding 
molecule(s) on the endothelial cell surface 
responsible for the galectin-3-mediated 
cytokine secretion. Using two different 
galectin-3 affinity purification processes we 
extracted four cell-membrane glycoproteins, 
CD146/MCAM/MUC18, CD31/PECAM-1, 
CD144/VE-cadherin, and CD106/Endoglin, 
from vascular endothelial cells. CD146 was the 
major galectin-3-binding ligand and strongly 
co-localized with galectin-3 on endothelial cell 
surfaces treated with exogenous galectin-3. 
Moreover, galectin-3 bound to N-linked 
glycans on CD146 and induced CD146 
dimerization and subsequent activation of AKT 
signalling. siRNA-mediated suppression of 
CD146 expression completely abolished the 
galectin-3-induced secretion of IL-6 and GCSF 
cytokines from the endothelial cells. Thus, 
CD146/MCAM is the functional galectin-3-
binding ligand on endothelial cell surfaces 
responsible for galectin-3-induced secretion of 
metastasis-promoting cytokines. We conclude 
that CD146/MCAM interactions with 
circulating galectin-3 may have an important 
influence on cancer progression and metastasis. 
 
Introduction 
Galectin-3 is a galactoside-binding protein that 
is expressed by many types of human cells. 
Overexpression of galectin-3 commonly occurs 
in most types of cancer (1,2) and is increasingly 
recognized to influence cancer cell-cell and 
cancer-microenvironment communications and 
contributes to cancer development, progression 
and metastasis as a result of galectin-3 
interaction with various galactose-terminated 
glycans carried on the cell surface and in the 
extracellular matrix(2).  
 
Earlier studies by ourselves as well as by other 
groups have revealed that the concentration of 
circulating galectin-3 is markedly increased up 
to 30-fold in the bloodstream of cancer patients 
including those with colorectal, breast, lung, 
bladder, pancreatic, head and neck cancers and 
melanoma(2-8). Patients with metastatic 
disease tend to have higher concentrations of 
circulating galectin-3 than those with only 
localized tumours (3). Our recent study has 
revealed that increased circulating galectin-3 is 
an important promoter of blood-borne 
metastasis in a mouse model (9). This effect of 
galectin-3 is shown to be partly attributed to 
galectin-3 interaction with the oncofetal 
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Thomsen-Friedenreich (Galβ1,3GalNAcα-, 
TF) 1  disaccharide expressed on the cancer-
associated transmembrane mucin protein 
MUC1(10,11), which is expressed by the 
majority of epithelial cancer cells (12). The 
galectin-3-MUC1 interaction induces MUC1 
cell surface polarization leading to exposure of 
the underlying adhesion molecules. This  
results in increased tumour cell heterotypic 
adhesion to the vascular endothelium as well as 
increased tumour cell homotypic aggregation to 
form tumour emboli (13). Circulating galectin-
3 is also shown to promote  metastasis by 
interaction with as yet unknown molecules on 
the endothelial cell surface and  induces 
endothelial secretion of cytokines Interleukin-6 
(IL-6), Granulocyte Colony-Stimulating Factor 
(G-CSF), Granulocyte-macrophage colony-
stimulating factor (GM-CSF) and Intercellular 
Adhesion Molecule-1(sICAM-1) (14).  
 
Pro-inflammatory cytokines such as IL-6 and 
G-CSF are important metastasis-promoters and 
are known to enhance various steps in the 
metastatic cascade including cancer-endothelial 
adhesion, cell proliferation, migration and 
angiogenesis(15,16). We showed that the 
increased secretion of these cytokines from the 
blood vascular endothelium generated by 
exogenous galectin-3 increases the expression 
of various adhesion molecules on the 
endothelial cell surface, including integrins and 
E-selectin either in an endocrine and/or 
paracrine way, resulting in increased cancer 
cell-endothelial adhesion, endothelial cell 
migration and angiogenesis (14). The galectin-
3 binding ligand(s) on the endothelial cell 
surface responsible for galectin-3 mediated-
endothelial secretion of these metastasis-
promoting cytokines however has remained 
unknown.   
 
We report in this study that CD146/MCAM 
(melanoma cell adhesion molecule, also known 
as MUC18) is the galectin-3 binding ligand on 
endothelial cell surface responsible for 
circulating galectin-3-mediated endothelial 
secretion of cytokines.  
                                                          
1
 Abbreviations: Gal3, galectin-3; G-CSF, 
granulocyte colony-stimulating factor; GM-
CSF, granulocyte-macrophage colony-
stimulating factor; HUVECs, human umbilical 
vein endothelial cells; HMVEC-Ls, human 
microvascular lung endothelial cells; sICAM-1, 
 
Results 
Galectin-3 induces cytokine secretion by 
micro- and macro-vascular endothelial cells.  
Our earlier study has reported that circulating 
galectin-3 induces secretion of IL-6, G-CSF, 
GM-CSF and ICAM-1 from human micro-
vascular endothelial cells (14).  Before 
proceeding to identify the endothelial cell 
surface galectin-3 binding molecules for 
galectin-3-induced cytokine secretion, we first 
compared the effect of galectin-3 on secretion 
of these cytokines from human micro- and 
macro-vascular endothelial cells.  It was found 
that the presence of galectin-3 at concentrations 
similar to those seen in cancer patients (3) 
increased secretion of IL-6, G-CSF, GM-CSF 
and ICAM-1 from human micro-vascular lung 
endothelial cells (HMVEC-Ls) and also from 
macro-vascular umbilical vein endothelial cells 
(HUVECs) (Fig 1). This suggests that the effect 
of galectin-3 on endothelial secretion of these 
cytokines can occur in both micro- and macro-
vasculature.  
 
Four endothelial cell membrane 
glycoproteins were extracted by galectin-3 
affinity purification   
Galectin-3 blotting/overlay demonstrated 
similar binding of galectin-3 to several proteins 
in HUVECs and HMVEC-Ls (Fig 2A). Two 
galectin-3 affinity purification approaches, His-
tagged recombinant galectin-3 conjugated to 
Nickel (Ni) and to agarose, were used to extract 
galectin-3 binding proteins from endothelial 
cells. After removal of unbound proteins, bound 
proteins were eluted from the columns with 
lactose. Various proteins ranging from ~50 to 
~250kDa were seen to be extracted by both the 
affinity purification processes shown by silver 
staining following SDS-PAGE (Fig 2B). Mass 
spectrometry analysis revealed a number of cell 
membrane and cytosolic proteins. The top 
scored cell membrane proteins in both the 
galectin-3-Ni and galectin-3-agarose affinity 
extracts were CD146/MCAM (melanoma cell 
adhesion molecule, MUC18), CD31/PECAM-
soluble intercellular adhesion molecule-1; IL-6, 
Interleukin-6;  MCAM, melanoma cell 
adhesion molecule, CD146, MUC18; PECAM, 
CD31, platelet endothelial cell adhesion 
molecule. 
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1(Platelet endothelial cell adhesion molecule), 
CD144/VE-cadherin, and CD106/Endoglin 
(11~28 peptides of each protein).  
 
CD146/MCAM is the major galectin-3 
binding protein on the endothelial cell 
surface. To confirm interaction of galectin-3 
with these cell membrane proteins, we treated 
the cells with galectin-3 followed by 
immunoprecipitation with antibodies against 
each of the four identified proteins. Galectin-3 
was predominately found in the 
immunoprecipitates of CD146/MCAM and 
CD106/Endoglin (Fig 3A), suggesting possible 
binding ligands among these proteins. In 
addition to galectin-3 and the 
antibody/immunoglobulin heavy and light 
chains, two other protein bands were also seen 
in the blots of the immunoprecipitates (Fig 3). 
As these two protein bands occurred in all the 
immunoprecipitates including the control IgG 
immunoprecipitates, they reflect non-specific 
antibody/immunogloblin binding.  
 
To further determinate interaction of galectin-3 
with these cell membrane proteins, we cross-
linked the cell surface proteins with a cleavable 
crosslinker DTSSP after treatment of the cells 
with recombinant galectin-3. Subsequent 
immunoprecipitation with antibodies against 
each of these proteins revealed presence of 
galectin-3 only in the CD146/MCAM 
immunoprecipitates (Fig 3B). This indicates 
that CD146/MCAM represents the major 
galectin-3 binding ligand on endothelial cell 
surface. Analysis by confocal microscopy 
showed weak expression of endogenous 
galectin-3 by the cells (Fig 4). Strong cell 
surface co-localization of CD146/MCAM with 
galectin-3 occurred when exogenous galectin-3 
was introduction (Fig 4).  
 
Galectin-3 binds to N-linked glycans 
expressed on CD146/MCAM.  
To gain insight into the interaction of galectin-
3 with CD146/MCAM, endothelial cells were 
first treated with N-glycanase (PNGaseF) or O-
glycanase (from Streptococcus pneumoniae) 
before treatment with recombinant galectin-3. 
The cells were lysed and immunoprecipitated 
with anti-CD146/MCAM antibody. Treatment 
of the cells with N-glycanase reduced the size 
of CD146/MCAM molecular weight in SDS-
PAGE as a result of reduction of N-linked sugar 
chains (Fig 5, top panel). Reduction of N-
glycans on CD146/MCAM substantially 
reduced (35%) the presence of galectin-3 in the 
immunoprecipitates (Fig 5, bottom panel) 
whilst treatment of the cells with O-glycanase 
showed no effect on galectin-3 presence in 
CD146/MCAM immunoprecipitates. This 
suggests that galectin-3 binds predominantly to 
N-linked glycans on CD146/MCAM.  
 
Suppression of CD146/MCAM expression 
abolishes galectin-3-induced cytokine 
secretion.  
To determine whether CD146/MCAM is the 
functional ligand responsible for galectin-3-
induced cytokine secretion of endothelium, we 
suppressed CD146/MCAM expression by 
siRNA. SiRNA treatment caused 80% 
reduction of cellular CD146/MCAM 
expression in comparison to the cells treated 
with control siRNA (Fig 6A). Suppression of 
CD146/MCAM expression completely 
abolished the effect of galectin-3 on endothelial 
secretion of IL-6 and G-CSF (Fig 6B and C). 
This indicates that CD146/MCAM is the 
galectin-3 binding receptor responsible for 
galectin-3-induced endothelial secretion of the 
cytokines.  
 
Galectin-3 induces CD146/MCAM 
dimerization and activation of down-stream 
AKT signalling.   
CD146/MCAM activity is known to be 
associated with CD146/MCAM dimerization 
(17,18) and downstream activation of AKT 
signalling (19-21). To determine whether 
galectin-3-CD146/MCAM interaction affects 
CD146/MCAM activity, we assessed 
CD146/MCAM dimerization and AKT 
activation in cell response to galectin-3. 
Introduction of galectin-3 caused a time-
dependent increase of CD146/MCAM 
dimerization which was detected in non-
denatured (Fig 7A) but not denatured SDS-
PAGE condition (Fig 7B). Galectin-3 treatment 
also caused similarly time-dependent increase 
of AKT phosphorylation (Fig7C) as 
CD146/MCAM dimerization.  
 
Galectin-3 activates several downstream 
signalling pathways.   
To gain further insight into the global effect of 
galectin-3 on endothelial cytokine secretion, we 
compared the activity of 46 tyrosine kinases in 
response to galectin-3 using a human Phospho-
Kinase array. Phosphorylation of several 
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tyrosine kinases was substantially increased in 
response to 24 hr treatment of endothelial cells 
with galectin-3 (Fig 8). These include HSP60 
(39 fold), WINK1 (13 fold), p27 (6.9 fold) β-
catenin (4.4 fold), c-jun (4 fold), p70 S6 Kinase 
(3.6 fold), Creb (2.2 fold), p53 (S392 and S15, 
2.8 fold and 1.8 fold respectively) and PRAS40 
(1.5 fold). This suggests that endothelial 
secretion of cytokines in response to galectin-3, 
which was shown previously to take several 
hours (14) and is shown in this study to be 
associated with binding of galectin-3 to cell 
surface CD146/MCAM (Fig6, 7), may involve 
multiple signalling pathways. The increased 
phosphorylation of PRAS40, a substrate of 
AKT, after 24 hr treatment of the cells with 
galectin-3 is in keeping with the increase in 
CD146/MCAM dimerization and AKT 
activation.   
 
Discussion 
This study shows that galectin-3 at 
concentrations similar to those found in the 
blood of cancer patients induces secretion of 
cytokines IL-6, G-CSF, GM-CSF and ICAM-1 
from both micro- and macro-vascular 
endothelial cells. CD146/MCAM is identified 
as the galectin-3 binding ligand on the 
endothelial surface responsible for galectin-3-
mediated secretion of cytokines. Galectin-3 
binds to N-glycans on CD146/MCAM and 
induces CD146/MCAM dimerization and 
downstream AKT activation.  
 
CD146/MCAM, also known as MUC18(22), is 
a type I transmembrane glycoprotein that 
contains 8 putative N-glycosylation sites on its 
extracellular domain(17). Its glycosylation 
accounts for about 35% of the molecular weight 
(23). CD146/MCAM was previously 
considered as an endothelial cell marker and 
used for identification of circulating endothelial 
cells(24). It is now known to be expressed also 
by melanoma cells(17) and associated with 
melanoma metastasis (25-27). There are two 
CD146/MCAM isoforms, CD146-long and 
CD146-short. The CD146-long form contains a 
63-aa intracellular domain including 2 putative 
endocytic domains and 5 potential protein 
kinase recognition sites, and the CD146-short 
form contains a truncated cytoplasmic tail 
lacking both of the endocytosis motifs and one 
of the protein kinase sites. Endothelial cells 
express both the long and short forms whereas 
melanoma cells express primarily the long 
isoform. 
 
CD146 is a member of the immunoglobulin 
superfamily of cell adhesion molecules and a 
key cell adhesion protein on the vascular 
endothelial cell surface. It is involved in various 
cell-cell and cell-matrix interactions in vascular 
endothelial activities such as cell migration and 
angiogenesis(17) and also engages in outside-in 
signalling. Although the natural CD146 ligand 
still remains elusive, its engagement is known 
to activate several signalling pathways 
including PI3K/AKT, p38 and PKC (17). 
CD146/MCAM interaction with VEGFR-2 on 
the endothelial cell surface has been shown to 
activate AKT and p38 signalling and increase 
cell migration (21).  Interaction of CD146 with 
Laminin-411 facilitates Th17 cell entry into the 
central nervous system (28). Binding of Netrin-
1 to CD146/MCAM was reported to activate an 
array of downstream signalling and increase 
endothelial cell proliferation, migration and 
angiogenesis (29). Recently, CD146 was 
reported to interact with exogenously 
introduced galectin-1 in endothelial cells and 
protects against galectin-1-induced cell 
apoptosis (30). Endogenous galectin-3 
expression in HUVECs was found to be low 
(Fig 4). Strong interaction and co-localization 
of CD146/MCAM with galectin-3 occurred 
when exogenous galectin-3 was introduced (Fig 
3 and 4).  
 
It remains to be determined exactly how 
CD146/MCAM activation in response to 
galectin-3 binding induces endothelial 
secretion of cytokines. The rapid activation of 
AKT indicates its involvement at the initial 
stage of signalling transduction. The activation 
of cellular WINK1, β-catenin, and HSP60 after 
24 hr galectin-3 treatment suggests possible 
involvement of multiple downstream signalling 
pathways at later stages of the process. Toll-like 
receptor-2-associated IL-6 secretion from 
megakaryocytes has been shown to be 
associated with WNT β-catenin signalling(31) 
and the presence of humanized anti-HSP60 
antibody suppresses IL-6 secretion from  
PBMCs (32). These studies suggest a role of 
WNT and HSP signalling in galectin-3-
mediated cytokine secretion.  
 
In addition to CD146/MCAM, CD31/PECAM-
1 and CD144/VE-cadherin were also seen in 
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this study to be extracted by galectin-3 affinity 
purification from endothelial cells (Fig 2 and 3). 
CD146 has been reported to be able to interact 
with vascular endothelial growth factor 
receptor-2 (VEGFR-2) and induce activation of 
AKT(21). Interestingly, a complex formed by 
CD31/VE-cadherin and CD144/PECAM is 
reported to be associated with VEGFR-2 in 
endothelial cells (33) and their interaction 
shows to affect VEGFR-2-associated AKT 
signalling. It is therefore possible that 
CD146/MCAM, CD31/VE-cadherin and 
CD144/PECAM may form a super-complex on 
the endothelial cell surface through VEGFR-2. 
This may explain the extraction of these four 
proteins by galectin-3 affinity purification (Fig 
2) even though galectin-3 may only bind to 
CD146/MCAM (Fig 3). The discovery that 
exogenous galectin-3 increases AKT activation 
(Fig 7), a downstream CD146/MCAM 
signalling that is associated also with VEGFR-
2 activation, is in keeping with this.   
 
CD146/MCAM is thus the functional galectin-
3 binding ligand on the endothelial cell surface 
responsible for galectin-3-induced endothelial 
secretion of metastasis-promoting cytokines. 
Many previous studies have shown that higher 
serum levels of pro-inflammatory cytokines 
(e.g. IL-6 and TNFα) correlate with advanced 
metastatic stages and poor survival in various 
types of cancer (34). These cytokines enhance 
various cell activities including proliferation, 
invasion, angiogenesis and metastasis (15,35). 
The increased secretion of IL-6, G-CSF and 
other cytokines from the vascular endothelium 
induced by interaction of circulating galectin-3 
with endothelial CD146/MCAM in cancer may 
therefore have an important influence on cancer 
progression and metastasis.  
 
Experimental procedures 
Materials 
Human Interleukin-6 (IL-6) and Granulocyte 
Colony-Stimulating Factor (G-CSF) ELISA 
kits were purchased from Peprotech, London, 
UK. Antibodies against CD146/MCAM (mab 
932), CD144/PECAM-1 (BBA7), CD31/VE-
Cadherin (MAB9381), Galectin-3 (mab 1154), 
biotinylated-anti-Galectin-3 (BAF1154) and 
Proteome Profiler Human Phospho-Kinase 
Array Kits (Ary003b) were from R&D 
Systems, Abingdon, UK. Antibodies against 
Endoglin (SC-18838) and pan-actin 5 were 
from Santa Cruz Biotechnology (Heidelberg, 
Germany) and Neomarkers (Fremont, Ca), 
respectively. Antibodies against AKT (9272S) 
and Phospho-AKT (Phospho T308, 13038S) 
were purchased from Cell Signalling (Hitchin, 
UK). DTSSP was purchased from Thermo 
Fisher Scientific, Runcorn, UK.  
 
Cells  
Human microvascular lung endothelial cells 
(HMVEC) and human umbilical vein 
endothelial cells (HUVEC) were obtained from 
Lonza (Basel, Switzerland) and cultured in 
EGM and EGM-2-MV media respectively. 
Cells with less than 6 passages were used in all 
experiments.  
 
Cytokine quantification 
HUVECs or HMVEC-Ls were seeded in 12-
well plates at 5x104cells/well and cultured for 
24 hr at 370C before introduction of 
recombinant galectin-3 for 24 hr. The culture 
medium was collected and centrifuged at 
1000rpm to remove any cell debris. The 
supernatant was used for determination of IL-6 
and G-CSF concentration using the IL-6 and G-
CSF ELISA kits according to the 
manufacturer’s instructions. 
 
Production of recombinant galectin-3 
Full-length recombinant human galectin-3 and 
His-tagged recombinant human galectin-3 were 
produced in E.coli as previously described(36). 
 
Galectin-3 affinity Purification 
Confluent HUVECs were washed once with 
100mM lactose/PBS and twice with PBS before 
being lysed in lysis buffer [PBS, 0.5% Triton 
X-100, 0.5% NP-40 (v/v), protease inhibitors]. 
The lysate was collected and sonicated 3x20 
seconds on ice. The lysate was cleared by 
centrifugation at 16000 x g for 10 min at 4°C 
and before application to galectin-3 affinity 
columns. Galectin-3-Ni (Nickel) column was 
prepared by injection of 12 mg His-tagged 
recombinant galectin-3 to a His-Trap HP 
column (GE healthcare). Galectin-3-agarose 
affinity beads were prepared by conjugating 30 
mg recombinant galectin-3 to 12.5 ml NHS-
agarose slurry beads (Pierce) according to 
manufacturer instructions. 
 
After removal of the unbound galectin-3 by 
three washes with PBS, the cell lysate was 
applied to the column three times. After 3 
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washes with PBS, the bound proteins were 
eluted with 0.2M lactose/PBS. The eluate was 
dialysed at 4°C for 24 hr against distilled water. 
The samples were freeze-dried and analysed by 
SDS-PAGE followed by silver staining or by 
mass spectrometry.  
 
Mass spectrometry and protein 
identification  
Sample preparation: A proportion of the 
freeze-dried eluate from both the galectin-3-
agarose and galectin-3-Ni columns was 
reconstituted in 500µL of 25mM ammonium 
bicarbonate (NH4HC03). 10µL of Strataclean 
resin (Agilent UK) was added to the sample 
followed by gentle vortexing for 1min. The 
samples were centrifuged at 2,000 x g for 2min 
and the protein-depleted sample aspirated and 
the resin washed three times with 1mL of 
25mM NH4HC03. The resin was re-suspended 
in 80µL of the same buffer and 5µL of 1%(w/v) 
Rapigest (Waters, UK) was added and the 
samples placed in a heating block set at 800C 
for 10min. Samples were reduced by the 
addition of 5µL of 60mM dithiothreitol in 
25mM NH4HC03 and incubated at 600C for 
10min. The samples were alkylated by the 
addition of 180mM iodoacetaminde in 25mM 
NH4HC03 followed by incubation at room 
temperature in the dark for 30min. Trypsin 
(Promega Gold) 5µL was added from a 
0.2mg/mL stock solution in 50mM acetic acid 
(~1:50 enzyme to protein ratio) and the samples 
incubated at 37°C overnight with continuous 
mixing.  
 
Mass spectrometry analysis: Data-dependent 
LC-MSMS analyses were conducted on a 
QExactive quadrupole-Orbitrap mass 
spectrometer coupled to a Dionex Ultimate 
3000 RSLC nano-liquid chromatograph 
(Hemel Hempstead, UK). Sample digest from 
the galectin-3 affinity chromatography was 
analysed using a 50min LC-MS method. Digest 
(1µL) was loaded onto a trapping column 
(Acclaim PepMap 100 C18, 75 µm x 2 cm, 3 
µm packing material, 100 Å) using a loading 
buffer of 0.1 % (v/v) TFA, 2 % (v/v) acetonitrile 
in water for 7 min at a flow rate of 9 µL min-1.  
The trapping column was then set in-line with 
an analytical column (EASY-Spray PepMap 
RSLC C18, 75 µm x 50 cm, 2 µm packing 
material, 100 Å) and the peptides eluted using a 
linear gradient of 96.2 % A (0.1 % [v/v] formic 
acid):3.8 % B (0.1 % [v/v[ formic acid in 
water:acetonitrile [80:20] [v/v]) to 50 % A:50 % 
B over 30 min at a flow rate of 300 nL min-1, 
followed by washing at 1% A:99 % B for 5 min 
and re-equilibration of the column to starting 
conditions.  A shorter 30min LC-MS method 
was used for the digest from His-galectin-3 
affinity chromatography due to the lower 
sample complexity. The column was 
maintained at 400C, and the effluent introduced 
directly into the integrated nano-electrospray 
ionisation source operating in positive ion mode. 
The mass spectrometer was operated in DDA 
mode with survey scans between m/z 300-2000 
acquired at a mass resolution of 70,000 
(FWHM) at m/z 200.  The maximum injection 
time was 250 ms, and the automatic gain 
control was set to 1e6.  The 10 most intense 
precursor ions with charges states of between 
2+ and 5+ were selected for MS/MS with an 
isolation window of 2 m/z units.  The maximum 
injection time was 100 ms, and the automatic 
gain control was set to 1e5.  Fragmentation of 
the peptides was by higher-energy collisional 
dissociation using normalised collision energy 
of 28%. Dynamic exclusion of m/z values to 
prevent repeated fragmentation of the same 
peptide was used with an exclusion time of 20 
sec.  
 
Raw data files were searched in Proteome 
Discoverer (v1.4) against the UniProt human 
reviewed database (20,187 sequences) using the 
Mascot search engine. Trypsin was specified as 
the protease with one missed cleavage allowed 
and with fixed carbamidomethyl modification 
for cysteine and variable oxidation 
modification for methionine. A precursor mass 
tolerance of 10 ppm and a fragment ion mass 
tolerance of 0.01 Da were applied. A peptide 
false discovery rate of 1-5% was applied. 
 
Immunofluorescence and confocal 
microscopy 
Sub-confluent HUVECs or HMVEC-Ls were 
seeded into 12-well plates inserted with glass 
coverslips. After 24 hr culture, the cells were 
treated with either galectin-3 or BSA (4 μg/ml) 
for 1 hr. After washing with PBS and fixed with 
4% paraformaldehyde, the cells were incubated 
with 1% BSA for 1 hr before application of 
biotinylated anti-galectin-3 (1:1000) or anti-
MCAM (1:1000) in 2% BSA/PBS (w/v) for 1 
hr at room temperature.  After three washes 
with PBS, the cells were incubated with FITC-
conjugated (1:2000) secondary antibody or 
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Texas Red-Avidin (1:2000) for 1 hr at room 
temperature. The cells were washed 5 times in 
PBS before being mounted using DAPI-
containing fluorescent mounting media (Vector 
Laboratories, Burlingame, CA). The slides 
were analysed with 3i confocal microscope 
(Marianas SDC, 3i Imaging) and Slidebook 6 
Reader version 6.0.4 (Intelligent-imaging). 
 
Co-Immunoprecipitation 
90% confluent HUVECs were first treated with 
galectin-3 (4µg/ml) for 1 hr at 370C  before 
being washed  with ice cold PBS and lysed with 
lysis butter (1% Triton X-100 in PBS) on ice for 
10 minutes. In some of the experiments, after 
treatment with galectin-3 (4µg/ml), the cells 
were washed and crosslinked with 2mM 
DTSSP for 1 hr on ice. After quenching the 
reaction with 20mM Tris buffer for 15 minutes, 
the cells were lysed and centrifuged at 10,000 x 
g for 10 min at 4⁰C. The supernatants were 
collected and pre-cleared with 30µl protein-
A/G PLUS-Agarose beads (sc-2003, Santa 
Cruz) for 1 hr at 4⁰C. The lysates were 
incubated with anti-MCAM antibody (2 μg/ml) 
or control isotype control IgG at 40C overnight. 
After addition of 30μl protein-A/G plus agarose 
beads for 4 hr, the beads were washed four 
times with ice cold PBS with 1% Triton X-100 
(v/v). Proteins were eluted from the beads by 
boiling in SDS-sample buffer and analysed by 
SDS-PAGE and western blotting.  
 
Western blotting 
Cell lysates or immunoprecipitates were 
separated by SDS-PAGE and transferred to 
nitrocellulose membrane. The membranes were 
blocked in 5% BSA(w/v)/0.05% Tween-
20/TBS before incubation with primary 
antibodies against MCAM, PECAM-1, VE-
Cadherin, Endoglin, galectin-3 or actin at a 
concentration of 1:1000 overnight at 40C. After 
3 washes with 0.05% Tween-20/TBS, the blots 
were incubated with peroxidase-conjugated 
anti-mouse or anti rabbit antibodies (1:5000) 
for 1 hr. After 6 washes with 0.05% Tween-
20/TBS, the blots were developed using 
chemiluminescence Super Signal kit and 
visualized with the Molecular Imager® Gel 
Doc™ XR System (Biorad). 
 
Protein de-glycosylation 
Following immunoprecipitation as described 
above, protein-A/G plus agarose beads were 
washed twice with ice cold 1% Triton X-
100/PBS before incubation with 5U PNGase F  
(F8435, Sigma) or 10mU O-glycanase  
(GK80090, Prozyme) overnight at 370C. The 
beads were washed twice with PBS and 
proteins were eluted from the beads by boiling 
in SDS-sample buffer and analysed by SDS-
PAGE and western blotting. 
 
siRNA protein knockdown  
Fifty percent confluent HMVEC-Ls were 
cultured in 12-well plates for 24 hr. MCAM 
siRNA (150pmol) (siGenome Smart pool 
human MCAM, Thermo Fisher) or control non-
target siRNA (siGenome control siRNA #1, 
Thermo Fisher) were incubated with 100µl 
serum free medium for 5 min.  DharmaFect 
Transfection Reagent-4 (Thermo Fisher) (2.5μl 
in 100µl serum free medium) was then 
introduced for 20 min at room temperature 
before 800 µl EGM2 medium was added. After 
16 hr incubation, the transfection medium was 
replaced with fresh medium for 24 hr. The cells 
were then either lysed by SDS-sample buffer 
for subsequent analysis for MCAM expression 
by immunoblotting or introduced with galectin-
3 for 24 hr at 370C before the IL-6 and G-CSF 
concentrations in the culture media were 
determined by ELISA. 
 
CD146/MCAM dimerization  
HMVEC-Ls were cultured in 12-wells plate at 
5x104cells/well for 1 day before treatment with 
galectin-3 (4µg/ml) for 0, 10, 30 and 60 min at 
370C. Cells were washed in ice cold PBS and 
lysed in SDS-sample buffer with or without 
beta-mercaptoethanol before analysis by SDS-
PAGE and western blotting. 
 
Protein phosphor-Kinase array 
90% confluent HUVECs were treated with 
4µg/ml galectin-3 or BSA for 24 hr. Cells were 
washed, lysed and analysed using Proteome 
Profiler Human Phospho-Kinase Array Kit 
(Ary003b) according to the manufacturer 
instructions. Membranes were visualized with 
the Molecular Imager® Gel Doc™ XR System 
and analysed using Image Lab software version 
5.2.1 (Biorad). 
 
Statistical analysis 
Unpaired t test for single comparison or one-
way analysis of variance (ANOVA) followed 
by Bonferroni test for multiple comparisons 
(SPSS 24t) were used where appropriate. 
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Differences were considered significant when 
p<0.05. 
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Figure legends 
Fig 1. Galectin-3 induces cytokine secretion 
from both human micro- and macro-
vascular endothelial cells. Human 
microvascular lung endothelial cells (HMVEC-
Ls) (A) and macrovascular umbilical vein 
endothelial cells (HUVECs) (B) were treated 
with BSA or galectin-3 for 24 hr and the 
concentrations of G-CSF, GM-CSF, IL-6 and 
ICAM-1 in the culture medium were 
determined. Data are presented as mean ± SEM 
of at least 3 independent experiments each in 
triplicate. ***p<0.001, **p<0.01. 
 
Fig 2. Identification of endothelial cell 
surface galectin-3 binding proteins. A: 
Galectin-3 blotting/overlay shows similar 
binding of galectin-3 to a number of proteins in 
HUVECs and HUVECs. B: Galectin-3 affinity 
purification and protein identification.  
HUVEC cell lysates were separated by SDS-
PAGE and stained by silver staining (left panel), 
or applied to Ni- or agarose-conjugated 
galectin-3 columns. Bound proteins were 
released by lactose and identified by mass 
spectrometry, or separated by SDS-PAGE and 
stained by silver staining (right panel).  
 
Fig 3. Identification of CD146/MCAM as the 
major galectin-3 binding protein. HUVECs 
were treated with galectin-3 (4µg) for 60 min. 
The cells were then treated without (A) or 
with (B) DTSSP crosslinker before 
immunoprecipitation with antibodies 
against MCAM, PECAM-1, PE-Cadherin, 
or endoglin and followed by 
immunoblotting with anti-galectin-3 
antibody and peroxidase-conjugated 
secondary antibody. Co-
immunoprecipitated galectin-3, the heavy 
(IgG-H) and light (IgG-L) chains of the 
antibody/immunoglobulin used in the 
immunoprecipitation are indicated by 
arrows. Additional arrows show non-
specific (NS) antibody/immunoglobulin 
binding.  
 
Fig 4. Co-localization of exogenous galectin-
3 with CD146/MCAM in HUVECs. After 
treatment of HUVECs without (top panel) or 
with (bottom panel) galectin-3 (4 ug/ml) for 60 
min, the cells were fixed and CD146/MCAM 
(green) and galectin-3 (red) 
immunohistochemistry was conducted and 
followed by confocal microscopy. Cell nuclei 
were stained by DAPI (blue).  
 
Fig 5. Galectin-3 binds to N-linked glycans 
on CD146/MCAM. After 
immunoprecipitation of HUVECs with anti-
CD146 antibody, the immunoprecipitates were 
treated with PNGaseF or O-glycanase before 
electrophoresis and immunoblotting with 
CD146/MCAM and galectin-3 antibody.  
 
Fig 6. Suppression of CD146/MCAM 
expression abolishes galectin-3-induced 
cytokine secretion. HUVECs were treated with 
control or CD146/MCAM siRNA for 36 he.  
The cells were then either lysed and analysed 
for CD146/MCAM expression by 
CD146/MCAM immunoblotting (A), or further 
treated with galectin-3 (4ug/ml) for 24 hr before 
the levels of G-CSF (B) or IL-6 (C) in the 
culture medium were determined. *p<0.5 
(unpaired t test).  
 
Fig 7. Galectin-3 induces CD146/MCAM 
dimerization and down-stream AKT 
signalling.  HUVECs were treated with 
galectin-3 (4ug/ml) for various times. The cells 
were lysed and applied to SDS-PAGE under 
non-denatured (A) or denatured (B) conditions 
and probed by anti-CD146/MCAM antibody. 
Cellular proteins were also probed with 
antibodies against p-AKT and AKT (C).  
 
Fig 8. Activation of multiple downstream 
signalling pathways.  HUVECs were treated 
with BSA (top panel) or galectin-3 (4ug/ml) 
(bottom panel) for 24 hr before the cells were 
lysed and analysed by Profiler human Phospho-
Kinase Array.  
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